349 related articles for article (PubMed ID: 24141789)
1. FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.
Khongkow P; Karunarathna U; Khongkow M; Gong C; Gomes AR; Yagüe E; Monteiro LJ; Kongsema M; Zona S; Man EP; Tsang JW; Coombes RC; Wu KJ; Khoo US; Medema RH; Freire R; Lam EW
Oncogene; 2014 Aug; 33(32):4144-55. PubMed ID: 24141789
[TBL] [Abstract][Full Text] [Related]
2. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment.
Monteiro LJ; Khongkow P; Kongsema M; Morris JR; Man C; Weekes D; Koo CY; Gomes AR; Pinto PH; Varghese V; Kenny LM; Charles Coombes R; Freire R; Medema RH; Lam EW
Oncogene; 2013 Sep; 32(39):4634-45. PubMed ID: 23108394
[TBL] [Abstract][Full Text] [Related]
3. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.
Millour J; de Olano N; Horimoto Y; Monteiro LJ; Langer JK; Aligue R; Hajji N; Lam EW
Mol Cancer Ther; 2011 Jun; 10(6):1046-58. PubMed ID: 21518729
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.
Khongkow P; Gomes AR; Gong C; Man EP; Tsang JW; Zhao F; Monteiro LJ; Coombes RC; Medema RH; Khoo US; Lam EW
Oncogene; 2016 Feb; 35(8):990-1002. PubMed ID: 25961928
[TBL] [Abstract][Full Text] [Related]
5. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance.
Karunarathna U; Kongsema M; Zona S; Gong C; Cabrera E; Gomes AR; Man EP; Khongkow P; Tsang JW; Khoo US; Medema RH; Freire R; Lam EW
Oncogene; 2016 Mar; 35(11):1433-44. PubMed ID: 26148240
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of FoxM1 sensitizes nasopharyngeal carcinoma cells to cisplatin via inhibition of MRN-ATM-mediated DNA repair.
Li D; Ye L; Lei Y; Wan J; Chen H
BMB Rep; 2019 Mar; 52(3):208-213. PubMed ID: 30638177
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 confers acquired cisplatin resistance in breast cancer cells.
Kwok JM; Peck B; Monteiro LJ; Schwenen HD; Millour J; Coombes RC; Myatt SS; Lam EW
Mol Cancer Res; 2010 Jan; 8(1):24-34. PubMed ID: 20068070
[TBL] [Abstract][Full Text] [Related]
8. The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment.
de Olano N; Koo CY; Monteiro LJ; Pinto PH; Gomes AR; Aligue R; Lam EW
Mol Cancer Res; 2012 Sep; 10(9):1189-202. PubMed ID: 22802261
[TBL] [Abstract][Full Text] [Related]
9. Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis.
Taylor AM; Groom A; Byrd PJ
DNA Repair (Amst); 2004; 3(8-9):1219-25. PubMed ID: 15279810
[TBL] [Abstract][Full Text] [Related]
10. Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks.
Takemura H; Rao VA; Sordet O; Furuta T; Miao ZH; Meng L; Zhang H; Pommier Y
J Biol Chem; 2006 Oct; 281(41):30814-23. PubMed ID: 16905549
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance.
Nestal de Moraes G; Delbue D; Silva KL; Robaina MC; Khongkow P; Gomes AR; Zona S; Crocamo S; Mencalha AL; Magalhães LM; Lam EW; Maia RC
Cell Signal; 2015 Dec; 27(12):2496-505. PubMed ID: 26404623
[TBL] [Abstract][Full Text] [Related]
12. ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance.
Ewald B; Sampath D; Plunkett W
Cancer Res; 2008 Oct; 68(19):7947-55. PubMed ID: 18829552
[TBL] [Abstract][Full Text] [Related]
13. RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment.
Kongsema M; Zona S; Karunarathna U; Cabrera E; Man EP; Yao S; Shibakawa A; Khoo US; Medema RH; Freire R; Lam EW
Oncogenesis; 2016 Aug; 5(8):e252. PubMed ID: 27526106
[TBL] [Abstract][Full Text] [Related]
14. FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression.
Li SK; Smith DK; Leung WY; Cheung AM; Lam EW; Dimri GP; Yao KM
J Biol Chem; 2008 Jun; 283(24):16545-53. PubMed ID: 18408007
[TBL] [Abstract][Full Text] [Related]
15. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.
Khongkow M; Olmos Y; Gong C; Gomes AR; Monteiro LJ; Yagüe E; Cavaco TB; Khongkow P; Man EP; Laohasinnarong S; Koo CY; Harada-Shoji N; Tsang JW; Coombes RC; Schwer B; Khoo US; Lam EW
Carcinogenesis; 2013 Jul; 34(7):1476-86. PubMed ID: 23514751
[TBL] [Abstract][Full Text] [Related]
16. Productive replication of human papillomavirus 31 requires DNA repair factor Nbs1.
Anacker DC; Gautam D; Gillespie KA; Chappell WH; Moody CA
J Virol; 2014 Aug; 88(15):8528-44. PubMed ID: 24850735
[TBL] [Abstract][Full Text] [Related]
17. NBS1 is regulated by two kind of mechanisms: ATM-dependent complex formation with MRE11 and RAD50, and cell cycle-dependent degradation of protein.
Zhou H; Kawamura K; Yanagihara H; Kobayashi J; Zhang-Akiyama QM
J Radiat Res; 2017 Jul; 58(4):487-494. PubMed ID: 28369484
[TBL] [Abstract][Full Text] [Related]
18. Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance.
Nestal de Moraes G; Bella L; Zona S; Burton MJ; Lam EW
Curr Drug Targets; 2016; 17(2):164-77. PubMed ID: 25418858
[TBL] [Abstract][Full Text] [Related]
19. Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin.
Folk WP; Kumari A; Iwasaki T; Pyndiah S; Johnson JC; Cassimere EK; Abdulovic-Cui AL; Sakamuro D
J Biol Chem; 2019 Apr; 294(14):5700-5719. PubMed ID: 30733337
[TBL] [Abstract][Full Text] [Related]
20. Differential DNA damage signaling accounts for distinct neural apoptotic responses in ATLD and NBS.
Shull ER; Lee Y; Nakane H; Stracker TH; Zhao J; Russell HR; Petrini JH; McKinnon PJ
Genes Dev; 2009 Jan; 23(2):171-80. PubMed ID: 19171781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
